United Therapeutics Corp.
1110 Spring Street
Silver Spring,
MD 20910
United States - Map
Phone: 301-608-9292
Fax: 301-608-9291
Web Site: http://www.unither.com
| United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular and infectious diseases, and cancer in the United States and Internationally. The companys products include Remodulin (treprostinil sodium) for the treatment of pulmonary arterial hypertension; and CardioPAL SAVI and Decipher Cardiac Monitors for the treatment of cardiac arrhythmias and ischemic heart disease. Its NDA filed products include Inhaled Treprostinil for pulmonary arterial hypertension and Oral Tadalafil for pulmonary hypertension. The companys Phase III products comprise of Oral Treprostinil for pulmonary arterial hypertension; and Phase II products include Beraprost-MR for pulmonary arterial hypertension, 3F8 MAb for neuroblastoma, Oral Treprostinil for Peripheral vascular disease, and CardioPAL SAVI Wireless Cardiac Event Monitors for Cardiac arrhythmias and ischemic heart disease. Its Phase I products include Inhaled Treprostinil for pulmonary arterial hypertension associated with Idiopathic pulmonary fibrosis, Inhaled Treprostinil with AERx Essence for Pulmonary hypertension, 8H9 MAb for Metastatic brain cancer, and Celgosivir for Hepatitis C. The companys pre-clinical products comprise Miglustat for Hepatitis C and Glycobiology Antiviral Agents for Hepatitis C and other infectious diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Ms. Martine Rothblatt Ph.D., J.D., MBA, 54
Founder, Chairman and Chief Exec. Officer |
$
1.45M |
$
19.69M | Dr. Roger A. Jeffs Ph.D., 47
Pres, Chief Operating Officer |
$
1.13M |
$
5.04M | Mr. John M. Ferrari , 54
Chief Financial Officer, Principal Accounting Officer and Treasurer |
$
555.00K |
$
799.00K | Mr. Paul A. Mahon J.d., 45
Exec. VP of Strategic Planning, Gen. Counsel and Corp. Sec. |
$
901.00K |
$
2.21M |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.46% Nasdaq 
0.22 (0.51%) 
Profile
